Background: Most patients with indolent NHL (follicular lymphoma or marginal zone lymphoma) experience multiple relapses throughout their lifetime. Patients that relapse within 24 months of initial therapy (POD24) have shortened overall survival. Better therapies are needed in the relapsed/refractory setting to improve the outcomes in indolent NHL. Axic…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.